Last reviewed · How we verify
Amphotericin B Deoxycholate
Amphotericin B binds to ergosterol in fungal cell membranes, creating pores that disrupt membrane integrity and cause cell death.
Amphotericin B binds to ergosterol in fungal cell membranes, creating pores that disrupt membrane integrity and cause cell death. Used for Systemic fungal infections (invasive aspergillosis, candidiasis, cryptococcosis), Leishmaniasis, Amphotericin B-responsive fungal infections in immunocompromised patients.
At a glance
| Generic name | Amphotericin B Deoxycholate |
|---|---|
| Also known as | Fungizone, Anforicin B, Conventional amphotericin B (CAB), Amphotericin B for injection |
| Sponsor | Drugs for Neglected Diseases |
| Drug class | Polyene antifungal |
| Target | Ergosterol |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | FDA-approved |
Mechanism of action
Amphotericin B is a polyene antibiotic that selectively binds to ergosterol, a sterol unique to fungal cell membranes, rather than cholesterol in human cells. This binding disrupts the lipid bilayer, creating channels that allow leakage of intracellular contents and ultimately leads to fungal cell lysis and death. The deoxycholate formulation is a conventional lipid-associated formulation that improves solubility but is associated with greater nephrotoxicity compared to newer lipid formulations.
Approved indications
- Systemic fungal infections (invasive aspergillosis, candidiasis, cryptococcosis)
- Leishmaniasis
- Amphotericin B-responsive fungal infections in immunocompromised patients
Common side effects
- Nephrotoxicity (acute kidney injury)
- Infusion-related reactions (fever, chills, rigors)
- Hypokalemia
- Anemia
- Hypomagnesemia
- Phlebitis at infusion site
Key clinical trials
- Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST) (PHASE3)
- Amphotericin B Versus Isavuconazole for Mucormycosis: A Comparative Efficacy and Safety Study
- Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis (PHASE2)
- Single High-dose of Liposomal Amphotericin B in Combination With B/F/TAF for HIV/AIDS-associated Talaromycosis (NA)
- A Trial to Compare Nebulized Amphotericin B and Nebulized Normal Saline as Maintenance in Patients With Chronic Pulmonary Aspergillosis (PHASE3)
- Combined Inhalational With Intravenous Amphotericin B Versus Intravenous Amphotericin B Alone for Pulmonary Mucormycosis (PHASE2)
- The PK/PD of Deoxycholic Acid Amphotericin B in Invasive Fungal Infection Patients With Sepsis/Septic Shock
- High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amphotericin B Deoxycholate CI brief — competitive landscape report
- Amphotericin B Deoxycholate updates RSS · CI watch RSS
- Drugs for Neglected Diseases portfolio CI